Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.4783
-0.0346 (-6.75%)
Mar 31, 2025, 2:25 PM EDT - Market open
Century Therapeutics Revenue
In the year 2024, Century Therapeutics had annual revenue of $6.59M with 194.81% growth. Century Therapeutics had revenue of $4.17M in the quarter ending December 31, 2024, with 1,457.09% growth.
Revenue (ttm)
$6.59M
Revenue Growth
+194.81%
P/S Ratio
6.12
Revenue / Employee
$43,927
Employees
150
Market Cap
41.16M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IPSC News
- 11 days ago - Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference - GlobeNewsWire
- 6 months ago - Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer - GlobeNewsWire
- 8 months ago - Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 10 months ago - Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 - Seeking Alpha
- 10 months ago - Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting - GlobeNewsWire